Pharma Focus America
Thermo Fisher Scientific - Chemical Products

Latest Issue
Get instant access to latest e-book

LATEST NEWS


Dec 2023

Kamau Therapeutics Reveals Clinical-Stage Gene Correction Technology for Life-Threatening Genetic Diseases After Emerging from Stealth Mode

Kamau Therapeutics a company in the clinicalstage of gene correction has recently emerged from stealth mode following a strategic deal with Graphite Bio


Dec 2023

BioGenCell Announces the Launch of its Fifth Clinical Trial Site for Chronic Limb-Threatening Ischemia in the United States

BioGenCell a leader in the field of personalized cell therapy solutions is pleased to announce the commencement of its fifth Phase II clinical trial site in the United States at the University of Maryland Medical Center


Dec 2023

Engeneic Has Been Granted "Fast-track" Designation by the FDA for Its Novel Armed Nanocell Drug Conjugate (ANDC) Aimed at Treating Pancreatic Cancer

EnGeneIC an innovative biopharmaceutical company leading the field of armed antibody therapeutics for oncology has achieved a significant milestone with the FDA granting FastTrack designation for its pancreatic cancer therapeutic


Dec 2023

Ten63 Therapeutics and Boehringer Ingelheim Enter Partnership for Multi-Target Drug Discovery

Ten Therapeutics a biotechnology company has unveiled a collaboration with Boehringer Ingelheim for multitarget drug discovery The partnership aims to discover innovative therapeutic molecules to address diseases


Dec 2023

Mendus and the Australasian Leukaemia & Lymphoma Group Collaborate to Broaden Clinical Trials Investigating Vididencel as a Maintenance Treatment for AML

Mendus AB a biopharmaceutical company specializing in immunotherapies for tumor recurrence has recently disclosed a partnership with the Australasian Leukaemia Lymphoma Group


Dec 2023

Osteal Therapeutics' VT-X7 Gets FDA Breakthrough Designation, Completes APEX-2 Trial Enrollment

Osteal Therapeutics has received Breakthrough Therapy Designation from the US Food and Drug Administration for VTX an investigational drug therapy targeting periprosthetic joint infection in the hip and knee

press releases

Alpha Cognition Announces FDA Acceptance of New Drug Application for ALPHA-1062 for Mild-to-Moderate Alzheimer’s Disease

Alpha Cognition Inc a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders is pleased to announce that the US Food and Drug Administration

Xilio Therapeutics Initiates Phase 1 Combination Trial of XTX101, a Tumor-Activated Anti-CTLA-4, and Releases Updated Phase 1 Monotherapy Data

Xilio Therapeutics Inc a clinicalstage biotechnology company discovering and developing tumoractivated immunooncology therapies for people living with cancer today announced the initiation of enrollment for its Phase clinical trial

Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Study

Synaffix BV a Lonza company focused on commercializing its clinicalstage platform technology for the development of antibodydrug conjugates with bestinclass therapeutic index

Phathom Pharmaceuticals' VOQUEZNA® (vonoprazan) Tablets NDA Accepted by FDA for Non-Erosive GERD Heartburn

Phathom Pharmaceuticals Inc a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases announced today the FDA

11 - 11

Dec 2023

12 - 14

Dec 2023

13 - 16

Dec 2023

14 - 16

Dec 2023

12th International

Rome, Italy

15 - 15

Dec 2023

18 - 18

Dec 2023

21 - 21

Dec 2023
Testing The WorldCelebrating 70 Years of Nalgene
ROUQETTE - Pharma Virtual Lab
Thermo Fisher Scientific - Powering the future together


  • 1

    Patient-Centric Clinical Trials: Shaping the Future of Medical Research

    Kate Williamson

    Kate, Editorial Team at Pharma Focus Europe, leverages her extensive background in pharmaceutical communication to craft insightful and accessible content. With a passion for translating complex pharmaceutical concepts, Kate contributes to the team's mission of delivering up-to-date and impactful information to the global Pharmaceutical community.

  • 2

    Decoding the Magic Number for Vaccine Booster Doses to Combat COVID-19: Why the Race for Developing New SARS-CoV-2 Vaccines Is Far from Over

    Ryan Varghese Mathew

    Ryan Varghese is a researcher affiliated with the Department of Pharmaceutical Sciences, Philadelphia College of Pharmacy, and Philadelphia, USA. His work spans a spectrum of topics from artificial intelligence to cancer theranostics and drug delivery in Alzheimer's disease. His specialization lies in the drug delivery modalities in chronic diseases. He has curated several articles on the lacunae in the Government’s public policies while providing solutions for the same. His recent work included the proposal on drug repurposing and affordable hospitalization to mitigate the risk stemming from COVID-19 in India. His current line of work lies in the efficient diagnosis and treatment of various cancers.

    Rushil Dalal

    Rushil Dalal is a researcher currently affiliated with the Ludwig-Maximilians-Universität München. With a formal education in Biotechnology, his current lines of work encompass the development of novel therapeutics for oncological malignancies. Previously, he was associated with the Tata Memorial Centre - Advanced Centre for Treatment, Research and Education in Cancer (TMC-ACTREC). During his tenure, he has contributed significantly to the Department of Clinical Pharmacology, with his research in oncogenomics, where he was on the quest to elucidate SNPs that amplified the occurrence of tobacco-related head and neck cancer.

    Jainam Karsiya

    Jainam Karsiya is a clinical pharmacist and medical affairs executive associated with RiverRoute Creative Group, India. His domain of work expands across the length and breadth of oncology, ranging from drug delivery and clinical therapeutics to precision oncology. He has prior experience in nanotechnology, theranostics, and health outcomes research. He has also contributed to the drafting of public policies in the healthcare sector.

    Dileep Kumar

    Dileep Kumar is an associate professor in the Department of Pharmaceutical Chemistry at Poona College of Pharmacy. He is a pioneer in his field with his forte in the treatment and novel drug delivery in Cancer and Alzheimer’s disease, especially adamantyl analogs as GluN2B selective NMDA receptor agonists. He is also an awardee of the Junior Research Fellowship from the National Medicinal Plant Board (NMPB) New Delhi, a Senior Research Fellowship from the University Grants Commission (UGC), a Teaching Assistantship, and an Institute Post-Doctoral Fellowship from IIT (BHU) Varanasi. He is the Guest Editor of prestigious journals like Current Topics in Medicinal Chemistry, Current Drug Target, combinatorial chemistry, and Molecules.

  • 3

    From Qubits to Proteins: Quantum Computing's Promise in Protein Folding

    Vidya Niranjan

    Vidya Niranjan, Ph.D. is a leading scientist and academic researcher excelling in computational biology. She has worked extensively on genome analysis, drug discovery, tools and database development. With extensive research experience of over 20 years, she has published over 100 research articles. She has bagged research funding worth 40 million USD from various government agencies and pharmaceutical companies. She is currently working on project related to quantum computing and protein folding funded by the Ministry of Electronics and Information Technology (MEITy) is an executive agency of the Union Government of the Republic of India in collaboration with Amazon AWS.



  • Information Technology

    How AI is Transforming the Pharma Industry

    The global pharmaceutical industry is currently facing many wide ranging challenges including an aging population increased life expectancy a rise in chronic conditions reduced funding for treatments reduced numbers of clinical staff the ever increasing cost of drug development and raw materials and supply chain issues